Comparative Pharmacology
Head-to-head clinical analysis: CORTROPHIN ZINC versus COSYNTROPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTROPHIN ZINC versus COSYNTROPIN.
CORTROPHIN-ZINC vs COSYNTROPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticotropin (ACTH) stimulates the adrenal cortex to release glucocorticoids, mineralocorticoids, and androgens. In gel formulation, zinc complex prolongs absorption, providing sustained adrenocortical stimulation.
Synthetic adrenocorticotropic hormone (ACTH) analog that stimulates adrenal cortex to secrete cortisol, corticosterone, and androgens.
40-80 units subcutaneously or intramuscularly every 24-72 hours, titrated to individual patient response.
250 mcg to 2500 mcg intramuscularly or intravenously, with 250 mcg being the most commonly used dose for cosyntropin stimulation test; frequency as needed per test protocol.
None Documented
None Documented
Terminal half-life: 16-24 hours; clinical context: prolonged due to zinc complex, allows once-daily dosing
Terminal elimination half-life is approximately 15 minutes; rapid clearance requires continuous infusion or frequent dosing for sustained effect.
Renal: ~90% as metabolites; biliary/fecal: ~10%
Primarily renal; >90% of dose excreted unchanged in urine; negligible biliary/fecal elimination.
Category C
Category C
Corticotropin
Corticotropin